×

Merck buys Idenix for $3.85 billion

9:06 AM ET Mon, 9 June 2014

Merck announced it will buy biotechnology company Idenix for $24.50 per share in cash, with the "Squawk on the Street" crew. Jim Cramer explains why he wasn't eyeing phase 2 data closely enough.